Entries by Thomas Gabrielczyk

BioNTech and Ryvu Therapeutics enter into global collaboration

Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.

Amsterdam Neogene Therapeutics aquired by AstraZeneca

AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer. The acquisition delivers an initial payment of $200m on deal closing, and a further up to $120m in both contingent milestones-based and non-contingent consideration.

Speedy DNA extraction from buccal swabs & FFPE samples

BioEcho Life Sciences develops innovative products that drastically improve the quality, convenience, and speed of standard molecular protocols. The EchoLUTION technology consists of an efficient and gentle lysis, followed by a unique single-step centrifugation, which provides a reduction of procedural steps compared to conventional kits, and considerably reduces plastic waste.

Vector BioPharma: the future of gene delivery

Precision gene delivery remains one of the greatest challenges in modern medicine. A Basel-based biopharma company, Vector BioPharma, has accepted the challenge and, with cutting-edge technology from the University of Zürich, is developing a revolutionary new way to deliver the right genes to the right place at the right time. Vector BioPharma aims to be the pioneer in delivering future medicines with this technology, now under development in multiple areas of urgent medical need.